Q-omics provides the consensus-scored ARFIP2 profile across patient tissues and cancer cell-line models. ARFIP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARFIP2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ARFIP2 protein abundance shows 23,354 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where ARFIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARFIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARFIP2 survival associations across molecular data types. ARFIP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARFIP2 RNA expression–survival associations across cancer types. High ARFIP2 expression shows unfavorable associations in ACC, LIHC, KICH and BLCA, but favorable associations in UCEC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARFIP2 RNA expression.
This table summarizes ARFIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARFIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARFIP2 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, BRCA, COAD and LUAD. The KICH box plot shows higher ARFIP2 RNA expression in normal versus tumor tissue (log2 FC = −1.171, t-test p < 0.001).
This table shows molecular features associated with ARFIP2 in patient tissues and cancer cell lines. In patient samples, ARFIP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARFIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
